|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
IL113010A
(en)
|
1994-03-31 |
1999-10-28 |
Pharmacia & Upjohn Ab |
Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
|
|
EP1621206A1
(en)
|
1994-12-12 |
2006-02-01 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric cytokines and uses thereof
|
|
AU6455896A
(en)
|
1995-07-11 |
1997-02-10 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
AT403764B
(de)
*
|
1996-03-15 |
1998-05-25 |
Immuno Ag |
Stabiler faktor viii/vwf-komplex
|
|
CA2252896C
(en)
|
1996-04-24 |
2009-03-10 |
The Regents Of The University Of Michigan |
Inactivation resistant factor viii
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
CA2329768C
(en)
|
1998-04-27 |
2008-06-10 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising factor viii and neutral liposomes
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
EP1351986A2
(en)
|
2001-01-12 |
2003-10-15 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
|
|
EP2110385A1
(en)
|
2001-06-14 |
2009-10-21 |
The Scripps Research Institute |
Stabilized factor VIII with engineered disulfide bonds
|
|
WO2003076567A2
(en)
|
2002-03-05 |
2003-09-18 |
Eli Lilly And Company |
Heterologous g-csf fusion proteins
|
|
WO2003093313A2
(en)
|
2002-04-29 |
2003-11-13 |
Baxter International Inc. |
Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
WO2004075923A2
(en)
|
2003-02-26 |
2004-09-10 |
Nektar Therapeutics Al, Corporation |
Polymer-factor viii moiety conjugates
|
|
ES2333598T5
(es)
|
2003-05-06 |
2013-09-04 |
Biogen Idec Hemophilia Inc |
Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
JP4629047B2
(ja)
|
2003-06-12 |
2011-02-09 |
イーライ リリー アンド カンパニー |
Ｇｌｐ−１アナログ複合タンパク質
|
|
BRPI0417916A
(pt)
|
2003-12-31 |
2007-04-10 |
Merck Patent Gmbh |
proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
KR101468345B1
(ko)
|
2004-11-12 |
2014-12-03 |
바이엘 헬스케어 엘엘씨 |
Ｆｖｉｉｉ의 부위 지향 변형
|
|
BRPI0519562A2
(pt)
|
2004-12-27 |
2009-01-27 |
Baxter Int |
construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
|
|
KR20080007226A
(ko)
|
2005-04-14 |
2008-01-17 |
체에스엘 베링 게엠베하 |
증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
KR20080108147A
(ko)
|
2006-03-31 |
2008-12-11 |
백스터 인터내셔널 인코포레이티드 |
페질화된 인자 ｖｉｉｉ
|
|
DK3896090T3
(da)
|
2006-06-14 |
2022-03-21 |
Csl Behring Gmbh |
Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
|
|
CA2673459C
(en)
|
2006-12-22 |
2016-09-13 |
Stefan Schulte |
Modified coagulation factors with prolonged in vivo half-life
|
|
AU2008261261B2
(en)
|
2007-06-13 |
2013-06-27 |
Csl Behring Gmbh |
Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
|
|
DK2865760T3
(en)
|
2008-06-24 |
2018-01-15 |
Csl Behring Gmbh |
Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
|
|
KR101808751B1
(ko)
|
2009-11-13 |
2017-12-13 |
그리폴스 테라퓨틱스 인코포레이티드 |
폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
EP2804623B1
(en)
|
2012-01-12 |
2019-08-07 |
Bioverativ Therapeutics Inc. |
Chimeric factor viii polypeptides and uses thereof
|
|
WO2013120939A1
(en)
|
2012-02-15 |
2013-08-22 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
|
WO2013083858A1
(en)
|
2012-04-24 |
2013-06-13 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
WO2013160005A1
(en)
|
2012-04-24 |
2013-10-31 |
Novo Nordisk A/S |
Pharmaceutical composition suitable for treatment of haemophilia
|
|
CN110054699A
(zh)
|
2012-07-11 |
2019-07-26 |
比奥贝拉蒂治疗公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
|
US20160207977A1
(en)
*
|
2013-06-12 |
2016-07-21 |
Novo Nordisk A/S |
Compounds Suitable for Treatment of Haemophilia
|
|
CA2949323A1
(en)
|
2014-06-06 |
2015-12-10 |
Octapharma Ag |
Preparation comprising factor viii and von willebrand factor peptides
|
|
BR112016030950A2
(pt)
|
2014-07-02 |
2018-03-27 |
Csl Ltd |
polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
|
|
US10772936B2
(en)
|
2015-05-22 |
2020-09-15 |
CSL Behring Lengnau AG |
Methods for preparing modified von Willebrand factor
|